Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Open accessThe DOI matches its Crossref record; 111 of the 112 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is a hormone secreted predominantly by the distal small intestine and colon and released in response to enteral nutrient exposure. GLP-1-based therapies are now used widely in the management of type 2 diabetes and have the potential to be effective antiobesity agents. Although widely known as an incretin hormone, there is a growing body of evidence that GLP-1 also acts as an enterogastrone, with profound effects on the gastrointestinal motor system. Moreover, the effects of GLP-1 on gastrointestinal motility appear to be pivotal to its effect of reducing postprandial glycaemic excursions and may, potentially, represent the dominant mechanism. This review summarizes current knowledge of the enterogastrone properties of GLP-1, focusing on its effects on gut motility at physiological and pharmacological concentrations, and the motor actions of incretin-based therapies. While of potential importance, the inhibitory action of GLP-1 on gastric acid secretion is beyond the scope of this paper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Blood glucose (a) and plasma insulin (b) concentrations during IV infusion of GLP-1, at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19], and used with permission from the publisher).](https://figures.cochat.ai/paper-figures/12ab264a4ad24a26a6cba2d995beab18/effects-of-glp-1-and-incretin-based-therapies-on-gastrointestinal-motor-function-figure-1.jpg)
![Figure 2 Relationship between the area under the plasma glucose concentration curve between 0 and 30 minutes and the retention of the meal in the stomach at 30 minutes (r = 0.65, P < .01) (adapted from Horowitz et al. 1993 [45] and used with the permission of the publisher).](https://figures.cochat.ai/paper-figures/9c0d556b035e4aa9a9b1a00b73ec14a4/effects-of-glp-1-and-incretin-based-therapies-on-gastrointestinal-motor-function-figure-2.jpg)
![Figure 3 Gastric emptying curves for the solid and liquid components of a meal for the total, proximal, and distal stomach during IV infusion of GLP-1 at 0.3 and 0.9 pmol/kg/minutes, or 0.9% saline, in 10 healthy humans. Data are means ± SEM. *GLP-1 0.3 and 0.9 versus saline: P < .05; #GLP-1 0.9 versus GLP-1 0.3: P < .05 (adapted from Little et al. 2006 [19] and used with permission from the publisher).](https://figures.cochat.ai/paper-figures/ce9fce815c1442429bc48b6a23974b19/effects-of-glp-1-and-incretin-based-therapies-on-gastrointestinal-motor-function-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RAs delay gastric emptying by inhibiting gastrointestinal motility through both PNS and CNS.”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, this promotes fundic relaxation, decreases peristalsis in the gastric antrum and duodenum, and increases pyloric sphincter tone, thereby delaying the transfer of gastric contents into the duodenum [29].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Constipation tended to last longer, and may be because of the effects of GLP‐1RAs on GI motility. 22”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 2×
“This has provided the rationale for the development, and subsequent widespread use, of synthetic longer-acting analogues, such as exenatide and liraglutide (the two approved GLP-1 analogues), and DPP-4 inhibitors, like sitagliptin and vildagliptin, to improve glycaemic control in type 2 diabetic patients [27].”
BackgroundThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
The mechanism of pancreatic secretion
Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,269
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 2×
“While these could relate to its effects on gastric motor function, and antral distension in particular [35, 36, 97], the occurrence of adverse effects seems not to relate closely to the delay in gastric emptying [81, 96], and it is possible that central mechanisms are important.”
BackgroundGut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995
Postprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945 · cited 1×
“Postprandial hyperglycaemia is being increasingly recognised as an independent predictor of cardiovascular mortality in both diabetic and nondiabetic populations [55, 56].”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“The insulinotropic property of GIP is markedly diminutesished in type 2 diabetic patients [89–91], probably in part as an effect of hyperglycaemia.”
Background
Research works printed but not linked: 14
- 1964, The Lancet, 284, 20
- 1997, American Journal of Physiology, 273, E981
- 2010, Neurogastroenterology & Motility, 22, article e1315, 1191
- 2004, Diabetes, Nutrition & Metabolism, 17, 336
- 1999, American Journal of Physiology, 277, G1217
- 1990, American Journal of Physiology, 259, G1031
- 1998, American Journal of Physiology, 275, R1293
- 1998, American Journal of Physiology, 275, R1308
- 1996, Journal of Nuclear Medicine, 37, 1643
- 1996, American Journal of Physiology, 271, G814
- 2002, American Journal of Physiology, 282, G424
- 2000, American Journal of Physiology, 278, G924
- 2010, Journal of Drug Design, Development and Therapy, 4, 279
- 2003, Diabetes, 52, A322
Cited by
Items 101–170 of 170
The Parenteral Feeding and Secretion of Regulatory Peptides in Infants
Tomasik, P. (2014) · Annual Research & Review in Biology · doi:10.9734/arrb/2014/11530 · Cited by 3
Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes
Lafferty, R. A., O'Harte, F. P. M., Irwin, N., Flatt, P. R., & Gault, V. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00035-9 · Cited by 3
Carrêlo, A. C. L. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 3
Asymptomatic Subcutaneous Semaglutide Overdose: A Case Report and Literature Review
Diec, C. B., Cook, E. A., & Nguyen, N. T. (2025) · Journal of Pharmacy Practice · doi:10.1177/08971900251335111 · Cited by 2
Funabashi, A., Ito, H., Maeda, M., Hasegawa, Y., Tsukioka, R., & Onda, M. (2025) · Pharmacy · doi:10.3390/pharmacy13050119 · Cited by 2
Zapp, C., Downer, D. M., Levine, A., Parker, N., Zapp, M., Downer, D. M., & Levine, L. (2026) · Cureus · doi:10.7759/cureus.102921 · Cited by 2
Chang, S., Tang, Y., Wang, M., Zhu, S., Tan, X., Fan, X., Lu, L., Duan, B., & Shen, L. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062121 · Cited by 2
Pharmacological Study of Weight Losing of Liraglutide Loaded within Layered Double Hydroxide Carrier
Sevan A. Dushan1, A. H. D. 2. (2020) · Indian Journal of Forensic Medicine & Toxicology · doi:10.37506/ijfmt.v14i4.11818 · Cited by 2
Mansour, A., Mohajeri‐Tehrani, M. R., Qorbani, M., Ghamari, M., Larijani, B. A., & Hosseini, S. (2020) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000463 · Cited by 2
Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide
Itoh, Y., Tani, M., Takahashi, R., & Yamamoto, K. (2024) · Diabetology International · doi:10.1007/s13340-024-00751-4 · Cited by 2
Great Weight, Low Pressure–One Problem: GLP-1 Receptor Agonist-Associated Colonic Ischemia
Ramrakhiani, H., Roorda, A. K., Tran, T., Shetler, K. P., & Triadafilopoulos, G. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08984-2 · Cited by 2
A Meta-Analysis of the Efficacy of Prokinetic Agents against Glycemic Control
Kim, Y., Chung, W. C., & Lee, S. J. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/3014973 · Cited by 2
Protein drug-drug interactions for therapeutic modalities
Liu, L., Evers, R., & Montgomery, D. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820018-6.00013-2 · Cited by 2
Grau Bové, M. C. (2021) · Rovira & Virgili repository · Cited by 2
Kang, D., & Choi, D. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.277 · Cited by 1
“Consequently, this promotes fundic relaxation, decreases peristalsis in the gastric antrum and duodenum, and increases pyloric sphincter tone, thereby delaying the transfer of gastric contents into the duodenum [29].”
Long-term Safety Profile of Semaglutide in the Management of Type 2 Diabetes and Obesity
Meng, Z. (2024) · MedScien · doi:10.61173/42stre19 · Cited by 1
Noguchi, T., Okamoto, M., Okamoto, M., Gotoh, K., Masaki, T., & Shibata, H. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag070 · Cited by 1
Belani, J. D. (2026) · Nutrients · doi:10.3390/nu18152578 · Cited by 1
Tu, S., Chiu, C.-F., Chou, C., Chuang, H., Fan, H.-C., Ko, W., Lee, C., Lin, W., Sung, Y., Tzeng, T., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70333 · Cited by 1
Glucagon-like peptide-1 based therapies: Effects beyond blood glucose control
Sivaraman, S., Barber, T. M., O'Hare, P. J., & Randeva, H. S. (2013) · The British Journal of Diabetes · doi:10.1177/1474651413504119 · Cited by 1
CGRP inhibitors and gastrointestinal tract
Kojecký, V. (2021) · Neurologie pro praxi · doi:10.36290/neu.2021.052 · Cited by 1
Olivera‐Nappa, Á., Contreras, S., Tevy, M. F., Medina-Ortiz, D., Leschot, A., Vigil, P., & Conca, C. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.831696 · Cited by 1
GLP-1 analogs: a comparison of new anti diabetic medications - presenting benefits and risks
Dębik, M., Szydłowski, Ł., Żurowska, K., Bednarski, A., Krużel, A., Ziajor, S., Sajdak, P., Tomasik, J. M., Stodolak, M., & Kłos, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.62.014 · Cited by 1
Effects of Resistance Exercise on Postprandial Metabolism in Obese Men with Prediabetes
Bittel, A. J. (2018) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/tdvz-6g03 · Cited by 1
Novas abordagens terapêuticas no tratamento da diabetes e obesidade
Leal, J. R. S. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Sivaraman, S. (2026) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33685810
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., & Costi, B. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_30
Inibição do transito gastrintestinal por antipsicoticos : estudo experimental da clozapina
Marques, A. C. (2015) · Americanae (AECID Library)
Marathe, C. S. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Self-citationA new long-acting GLP-1 derivative 6- KTP ameliorates body weight and lipid metabolism in DIO micePreprint
Wang, P., & Ran, Y. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/846717
Development of protocols to identify high hunger and low satiety phenotypes
Elfarssi, H. M. (2019) · Sheffield Hallam University · doi:10.7190/shu-thesis-00370
Pathophysiologie des Magen-Darm-Traktes
Roeb, E. (2013) · Springer eBooks · doi:10.1007/978-3-642-29773-1_3
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., Costi, B. B., & Cardoso, A. C. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_31
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
Sakamoto, N., Hamada, S., Takahashi, H., Satou, R., Suzuki, M., & Maeno, T. (2023) · Cureus · doi:10.7759/cureus.50075
Kalinkova, M., Kadiyska, T., Dabchev, K., Bogdanov, G., & Handjieva‐Darlenska, T. (2024) · Acta Medica Bulgarica · doi:10.2478/amb-2024-0041
Long-term Safety Profile of Semaglutide in the Management of Type 2 Diabetes and Obesity
Meng, Z. (2025) · MedScien · doi:10.61173/rvr8p069
The pleiotropic effects of liraglutide in obesity-linked diseases
Kozdrowicki, M., Kaleta, K., Kajtel, A., Tekieli, B., Kęska, M., Lorkowska-Zawicka, B., & Bujak-Giżycka, B. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.2.2
Gao, Y., Li, H., Wu, Q., Chen, B., Xu, K., Li, C., & Shen, Y. (2025) · Foods · doi:10.3390/foods14162800
Liraglutide Increases Gastric Fundus Tonus and Reduces Food Intake in Type 2 Diabetic Rats
Carrêlo, A. C. L., Martins, B. D., Seiça, R. M. F., Ribeiro, C., Matafome, P. N., & Silva, S. (2025) · Diabetology · doi:10.3390/diabetology6090096
Physiology and Pathophysiology of the Gastrointestinal Tract
Roeb, E. (2025) · Springer eBooks · doi:10.1007/978-3-032-00818-3_1
Martins, B. D. O. (2018) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
The incretin abc's in helath and disease-novel approaches to obesity and diabetes treatment
João, A. L. D. N. F. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Ali, S. S., Khanum, K. B., Abdullah, M. A. A., Elhassan, K. S. O., & Sharri, S. M. A. (2025) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2025.33.3.0501
AKSU, S. İ., & DEPREM, T. (2025) · Mediterranean veterinary journal. · doi:10.24880/meditvetj.1664403
Jindal, V. (2025) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/3749
Lee, J. Y. (2026) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2025.0088
Glucagon-Like Peptide-1 Receptor Agonists in Managing High Stoma Output: A Scoping Review
Mao, C., Wang, A. J., & Le, K. D. R. (2026) · Journal of Surgical Research · doi:10.1016/j.jss.2026.03.080
Güncel Anesteziyoloji ve Ağrı Çalışmaları XI
Kabahasanoğlu, K., Göktaş, T., Kaynak, A., Kaynak, M., Sarı, M. Y., SEVGİLİ, A., Celık, A. G., Doğan, A. K., Bektaş, M. H., & Güleş, E. (2026) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.4128
[Semaglutide-induced acute-on-chronic liver failure: A case report and literature review].
Fu, R., Wu, H., Huang, H., & Sun, B. (2026) · PubMed Central · doi:10.11817/j.issn.1672-7347.2026.250330
Gut Hormone Changes After Bariatric Surgery
Turner, B., & Kindel, T. L. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_7
Park, H. J., Oh, Y. E., Chi, S. A., Kim, M., Kim, J. E., Hong, S. N., Min, B., Kim, Y.-H., Chang, D. K., Kim, T., et al. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.121313
Upadhyaya, A., & Brown, J. (2026) · International journal of research and scientific innovation · doi:10.51244/ijrsi.2026.1306000479
Kim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
Chimango, R., & Dash, S. (2026) · International Journal of Pharmaceutical Research and Development · doi:10.33545/26646862.2026.v8.i7b.412
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Matsuo, Y., Okada, A., Sakamoto, T., & Yasunaga, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71189
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
Cardiovascular effects of incretin receptor agonists: beyond glycemic control
Ravić, M. P., Srejovic, I. M., Milosavljević, I., Novakovic, J. N., Jakovljević, V., Vučićević, K., Petrovic, D., & Muric, M. D. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0184
Chiu, C.-F., Chou, C., Hu, S.-W., Huang, K., Wu, Y.-L., Wu, H.-F., Liu, Y.-L., Yang, Y.-C., Chen, H., & Yeung, C. (2026) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2026.09.001
Side effects of GLP-1-based weight loss therapies
Paul, P. K. (2025) · Lu Zone Ul (Laurentian University)
Cisneros, J. Z., Camilleri, M., & Grover, M. (2026) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/agl.v56i3.690
Moore, T., & Ramsahoye, B. (2026) · Saudi Journal of Anaesthesia · doi:10.4103/sja.sja_314_26
Halawani, R. A. M. (2024) · Review of Contemporary Philosophy
Martins, B. D. O. (2018) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Abdalqadir, N. (2024) · TSpace (University of Toronto)
Olivera-Nappa, Á., Contreras, S., Tevy, M. F., Medina-Ortiz, D., Leschot, A., Vigil, P., & Conca, C. (2022) · doi:10.3389/fnut.2022.831696.s001
Metadata
- Authors
- Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M.
- Affiliations
- Royal Adelaide Hospital (AU)
- Corresponding author
- Rayner, Christopher K.
- Venue
- Experimental Diabetes Research
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-10
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3124003
- OpenAlex
- W2065444806
- Cited by
- 138
- References
- 112
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 20 · 2023: 3 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 10 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 9 · 2014: 6 · 2013: 12 · 2012: 1
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, incretin-based therapy, gastrointestinal motility, enterogastrone, type 2 diabetes, anti-obesity, gastric emptying, gastric acid secretion
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Gastrointestinal Hormones, Gastrointestinal Motility, Humans, Movement, Peptides, Gastrointestinal Tract, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.